1211531-07-5

Usage

Uses

Used in Organic Synthesis:
Tert-butyl di(but-3-en-1-yl)carbaMate is used as a reagent for the protection of amine groups in organic synthesis. Its application is crucial for preventing unwanted side reactions involving amines, thus enabling selective reactions to occur with other functional groups present in the molecule.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, tert-butyl di(but-3-en-1-yl)carbaMate is used as an intermediate for the synthesis of various biologically active compounds. Its ability to protect amine groups is particularly useful in the development of new drugs, where selective reactions are often required to achieve the desired molecular structures.
Used in Agricultural Industry:
Tert-butyl di(but-3-en-1-yl)carbaMate is also utilized in the agricultural industry as an intermediate for the synthesis of biologically active compounds. These compounds can be used as pesticides, herbicides, or other agrochemicals, where the selective protection of amine groups is essential for the development of effective and targeted products.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 124-02-7 diallylamine 
• 18940-41-5 di(but-3-en-1-yl)amine 

Downstream Products

• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 1263282-12-7 (Z)-2,3,6,7-tetrahydro-1H-azepine hydrochloride 
• 74-85-1 ethene 
• 85838-94-4 N-Boc-1,2,3,6-tetrahydropyridine 

Relevant academic research and scientific papers

Low catalyst loadings in olefin metathesis: Synthesis of nitrogen heterocycles by ring-closing metathesis

(Chemical Equetion Presentation) A series of ruthenium catalysts have been screened under ring-closing metathesis (RCM) conditions to produce five-, six-, and seven-membered carbamate-protected cyclic amines. Many of these catalysts demonstrated excellent RCM activity and yields with as low as 500 ppm catalyst loadings. RCM of the five-membered carbamate series could be run neat, the six-membered carbamate series could be run at 1.0 M, and the seven-membered carbamate series worked best at 0.2-0.05 M.

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma

Pim kinases have been targets of interest for a number of therapeutic areas. Evidence of durable single-agent efficacy in human clinical trials validated Pim kinase inhibition as a promising therapeutic approach for multiple myeloma patients. Here, we report the compound optimization leading to GDC-0339 (16), a potent, orally bioavailable, and well tolerated pan-Pim kinase inhibitor that proved efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models and has been evaluated as an early development candidate.

Design and synthesis of potent "sulfur-free" transition state analogue inhibitors of 5′-methylthioadenosine nucleosidase and 5′-methylthioadenosine phosphorylase

5′-Methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN) is a dual substrate bacterial enzyme involved in S-adenosylmethionine (SAM) related quorum sensing pathways that regulates virulence in many bacterial species. MTANs from many bacteria are directly involved in the quorum sensing mechanism by regulating the synthesis of autoinducer molecules that are used by bacterial communities to communicate. In humans, 5′-methylthioadenosine phosphorylase (MTAP) is involved in polyamine biosynthesis as well as in purine and SAM salvage pathways and thus has been identified as an anticancer target. Previously we have described the synthesis and biological activity of several aza-C-nucleoside mimics with a sulfur atom at the 5′ position that are potent E. coli MTAN and human MTAP inhibitors. Because of the possibility that the sulfur may affect bioavailability, we were interested in synthesizing "sulfur-free" analogues. Herein we describe the preparation of a series of "sulfur-free" transition state analogue inhibitors of E. coli MTAN and human MTAP that have low nano-to picomolar dissociation constants and are potentially novel bacterial anti-infective and anticancer drug candidates.